


46 (8)

J Rheumatol 2019;46;869-1060
<http://www.jrheum.org/content/46/8.citation>

1. Sign up for TOCs and other alerts
<http://www.jrheum.org/alerts>
2. Information on Subscriptions
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.



The Journal of Rheumatology

VOLUME 46: NO. 8

jrheum.org

AUGUST 2019

Editorials

- Assessment of Enthesitis in Psoriatic Arthritis
P.S. Helliwell 869
- Treatment of Lyme Arthritis *A.C. Steere* 871

Rheumatoid Arthritis

- Effect of Concomitant DMARD and MTX Administration Route on Biologic Treatment Durability in RA: OBRI Cohort Results *A.N. Lau, J.C. Thorne, M. Movahedi, et al, and the OBRI Investigators* 874
- MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic DMARD in RA
C. Peterfy, J. DiCarlo, P. Emery, et al. 887

Spondylitis

- Clinical Characteristics of Patients with SpA in Japan in Comparison with Other Regions of the World
M. Kishimoto, K. Yoshida, N. Ichikawa, et al 896

Psoriatic Arthritis

- Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with PsA, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study
P. Macchioni, C. Salvarani, N. Possemato, et al 904

Systemic Lupus Erythematosus

- Improvement of Outcomes in Patients with Lupus Nephritis: Management Evolution in Chinese Patients from 1994 to 2010
S.J. Shao, J.H. Hou, G.T. Xie, et al 912

Systemic Sclerosis

- Economic Burden among Commercially Insured Patients with SSc in the United States
Z. Zhou, Y. Fan, W. Tang, et al. 920

Vasculitis

- Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis
G. Tomasson, J.T. Farrar, D. Cuthbertson, et al, for the Vasculitis Clinical Research Consortium 928

Myositis

- Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease
T. Fujisawa, H. Hozumi, H. Yasui, et al 935

Pediatric Rheumatology

- Pediatric Antibiotic-refractory Lyme Arthritis: A Multicenter Case-control Study
D.B. Horton, A.J. Taxter, A.L. Davidow, B. Groh, D.D. Sherry, C.D. Rose 943
- Intraarticular Glucocorticoid Injection as Second-line Treatment for Lyme Arthritis in Children
D.B. Horton, A.J. Taxter, A.L. Davidow, B.P. Groh, D.D. Sherry, C.D. Rose 952

Images in Rheumatology

- A Great Masquerader: Chronic Active Epstein-Barr Virus for the Rheumatologist
A. Chhabra, R. Alyazidi, A. Human 960

OMERACT 2018: International Consensus Conference on Outcome Measures in Rheumatology, Terrigal, Australia, May 2018

- Introduction
L. March, B. Richards, M. Gill, et al. 962

Free online via JRheum Full Release option

Contents continued on page xii

Workshops and Special Sessions

The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders <i>S. Ramiro, M.J. Page, S.L. Whittle, et al</i>	969
Uptake of the OMERACT-OARSI Hip and Knee OA Core Outcome Set: Review of RCT from 1997 to 2017 <i>T.O. Smith, M. Mansfield, G.A. Hawker, et al</i>	976
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OA <i>T.O. Smith, G.A. Hawker, D.J. Hunter, et al</i>	981
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess PsA-specific Health-related Quality of Life in Clinical Trials <i>A.M. Orbai, R. Holland, Y.Y. Leung, et al</i>	990
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 PsA Workshop Report <i>A. Duarte-García, Y.Y. Leung, L.C. Coates, et al</i>	996
Establishing an Updated Core Domain Set for Studies in JIA: A Report from the OMERACT 2018 JIA Workshop <i>E.M. Morgan, J.E. Munro, J. Horonjeff, et al</i>	1006
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology <i>L.J. Maxwell, D.E. Beaton, B.J. Shea, et al</i>	1014
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies <i>M. Boers, D.E. Beaton, B.J. Shea, et al</i>	1021

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology <i>D.E. Beaton, L.J. Maxwell, B.J. Shea, et al</i>	1028
The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study <i>V.S. Sloan, S. Grosskleg, G. Wells, J.A. Singh</i>	1036
Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development <i>S. Humphrey-Murto, R. Crew, B. Shea, et al</i>	1041
The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future <i>C.A. Flurey, P.S. Tugwell, R.J. Black, et al</i>	1047
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for RCT <i>K.M. Andersen, J.T. Cheah, L. March, et al</i>	1053

Letter

Thirty Years of Followup in 3 Patients with Familial Polyarteritis Nodosa due to Adenosine Deaminase 2 Deficiency <i>J. Liebowitz, D.B. Hellmann, O. Schnappauf</i>	1059
---	------

Meetings	vi
---------------------------	----